Competing interests
MC has received honoraria from GT1, Eli Lilly, and Novartis; has been a consultant for AbbVie, Accord Healthcare, Amgen, AstraZeneca/MedImmune, Daiichi Sankyo Europe GmbH, Gilead, GSK, Lilly, Menarini, MSD, Novartis, Pfizer, Pierre Fabre, Sandoz-Novartis, Sanofi, Seagen, Seattle Genetics, and Servier; has been part of a speakers bureau for Amgen, Lilly, and Novartis; has received research grant/funding (institution) from Novartis; has received travel/accommodation/expense funds from AstraZeneca, Novartis, and Pfizer; and reports other relationships with Roche. F-CB has received payment or honoraria for lectures, presentations, or speakers bureaus from AstraZeneca, General Electric Health, Lilly, Menarini, Pfizer, Roche, and Sanofi; has participated on a data safety monitoring board or advisory board for AstraZeneca, General Electric Health, Lilly, Menarini, Pfizer, and Roche. PN reports nothing to disclose. UDG has received consulting fees from Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Novartis, PharmaMar, Pfizer, and Roche. BL, GP, LW, and YD are employees of Sanofi and may hold shares and/or stock options in the company. CH was an employee of Sanofi at the time this study was conducted.